OverviewSuggest Edit

Amphastar Pharmaceuticals, Inc. is a recognized specialty pharmaceutical company that uses state-of-the-art, cGMP compliant facilities to develop, manufacture, and market injectable and inhalation products. Amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. Its products include Enoxaparin Sodium Injection, Cortrosyn, Amphadase, Emergency Syringes in Luer-Jet, Lidocaine, Naloxone, and Phytonadione Injection.

TypePublic
Founded1996
HQRancho Cucamonga, US
Websiteamphastar.com
Employee Ratings2.3

Latest Updates

Employees (est.) (Dec 2019)2,027(-2%)
Job Openings2
Revenue (FY, 2019)$322.4 M(+10%)
Share Price (Sept 2020)$18.8 (-4%)
Cybersecurity ratingFMore

Key People/Management at Amphastar Pharmaceuticals

Jack Y. Zhang

Jack Y. Zhang

Chief Executive Officer, President, Chief Scientific Officer, and Director
Mary Z. Luo

Mary Z. Luo

Chief Operating Officer, Chief Scientist, and Chairman of the Board of Directors
Jacob Liawatidewi

Jacob Liawatidewi

Executive VP of Corporate Administration Center, Sales, and Marketing
Richard Koo

Richard Koo

Director
Richard Prins

Richard Prins

Director
Howard Lee

Howard Lee

Director
Show more

Amphastar Pharmaceuticals Office Locations

Amphastar Pharmaceuticals has offices in Rancho Cucamonga, Nanjing Shi and Éragny-sur-Epte
Rancho Cucamonga, US (HQ)
11570 6th St
Nanjing Shi, CN
5 Xinghe Rd, Qixia Qu
Éragny-sur-Epte, FR
1 Route Nationale 15 Paris Dieppe
Show all (3)

Amphastar Pharmaceuticals Financials and Metrics

Amphastar Pharmaceuticals Revenue

Embed Graph
View revenue for all periods
Amphastar Pharmaceuticals's revenue was reported to be $322.36 m in FY, 2019
USD

Revenue (Q2, 2020)

85.8m

Gross profit (Q2, 2020)

33.2m

Gross profit margin (Q2, 2020), %

38.7%

Net income (Q2, 2020)

(1.4m)

EBIT (Q2, 2020)

(2.9m)

Market capitalization (21-Sept-2020)

897.5m

Closing stock price (21-Sept-2020)

18.8

Cash (30-Jun-2020)

87.4m

EV

874.8m
Amphastar Pharmaceuticals's current market capitalization is $897.5 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

210.5m251.5m255.2m240.2m294.7m322.4m

Revenue growth, %

20%1%

Cost of goods sold

159.2m174.2m151.0m149.4m187.7m190.4m

Gross profit

51.3m77.3m104.2m90.8m107.0m131.9m
Annual
USDY, 2012Y, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

50.2m53.6m67.8m66.1m72.4m65.6m86.3m73.7m

Accounts Receivable

22.9m33.2m26.8m36.0m52.2m45.4m

Prepaid Expenses

9.8m5.5m9.5m

Inventories

118.4m63.6m69.3m110.5m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(10.7m)(2.8m)10.5m4.5m(6.7m)46.5m

Depreciation and Amortization

12.0m15.4m16.5m18.1m

Inventories

9.1m(9.7m)18.7m(6.0m)(41.1m)

Accounts Payable

7.0m6.7m29.2m(11.7m)
Show all financial metrics

Amphastar Pharmaceuticals Operating Metrics

FY, 2016

Facilities

5

Products

19
Show all operating metrics

Amphastar Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

F

58/100

SecurityScorecard logo

Amphastar Pharmaceuticals Revenue Breakdown

Embed Graph

Amphastar Pharmaceuticals revenue breakdown by business segment: 94.1% from Finished pharmaceutical products and 5.9% from Active Pharmaceutical Ingredients

Amphastar Pharmaceuticals Online and Social Media Presence

Embed Graph

Amphastar Pharmaceuticals News and Updates

Amphastar Pharmaceuticals to Present at the BMO Prescriptions for Success Healthcare Conference

RANCHO CUCAMONGA, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operati…

Amphastar Pharmaceuticals to Present at the Raymond James Virtual 2020 Human Healthcare Innovation Conference

RANCHO CUCAMONGA, Calif., June 12, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operati…

Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) Multiple-Dose Vial

RANCHO CUCAMONGA, Calif., June 09, 2020 (GLOBE NEWSWIRE) -- Amphastar® Pharmaceuticals, Inc., (NASDAQ: AMPH) (“Amphastar”), today announces that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Succinylcholine Chloride Injection USP, 200 …

Amphastar Pharmaceuticals Receives FDA Approval for Supplement to its Abbreviated New Drug Application for Sodium Bicarbonate Injection, USP 8.4%, 50mEq/50mL

RANCHO CUCAMONGA, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the U.S. Food and Drug Administration (“FDA”) granted approval of its supplemental Abbreviated New Drug Application for Sodium Bicarbonate Injection, USP, 8.4%, 50mEq/50m…

Amphastar Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference

RANCHO CUCAMONGA, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 1:00 p.m. Easte…

Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

RANCHO CUCAMONGA, Calif., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President will be presenting at the Jefferies London Healthcare Conference on Thursday, November 21, 2019 at 3:20 p.m. GMT in Aldwych, London, UK.
Show more

Amphastar Pharmaceuticals Frequently Asked Questions

  • When was Amphastar Pharmaceuticals founded?

    Amphastar Pharmaceuticals was founded in 1996.

  • Who are Amphastar Pharmaceuticals key executives?

    Amphastar Pharmaceuticals's key executives are Jack Y. Zhang, Mary Z. Luo and Jacob Liawatidewi.

  • How many employees does Amphastar Pharmaceuticals have?

    Amphastar Pharmaceuticals has 2,027 employees.

  • What is Amphastar Pharmaceuticals revenue?

    Latest Amphastar Pharmaceuticals annual revenue is $322.4 m.

  • What is Amphastar Pharmaceuticals revenue per employee?

    Latest Amphastar Pharmaceuticals revenue per employee is $159 k.

  • Who are Amphastar Pharmaceuticals competitors?

    Competitors of Amphastar Pharmaceuticals include Vitality Biopharma, Mylan and Horizon Therapeutics.

  • Where is Amphastar Pharmaceuticals headquarters?

    Amphastar Pharmaceuticals headquarters is located at 11570 6th St, Rancho Cucamonga.

  • Where are Amphastar Pharmaceuticals offices?

    Amphastar Pharmaceuticals has offices in Rancho Cucamonga, Nanjing Shi and Éragny-sur-Epte.

  • How many offices does Amphastar Pharmaceuticals have?

    Amphastar Pharmaceuticals has 3 offices.